TY - JOUR
T1 - Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab
T2 - Correlation of Radiographic and Pathologic Treatment Effect
AU - Merlino, Dante J.
AU - Johnson, Jennifer M.
AU - Tuluc, Madalina
AU - Gargano, Stacey
AU - Stapp, Robert
AU - Harshyne, Larry
AU - Leiby, Benjamin E.
AU - Flanders, Adam
AU - Zinner, Ralph
AU - Axelrod, Rita
AU - Curry, Joseph
AU - Cognetti, David M.
AU - Mannion, Kyle
AU - Kim, Young J.
AU - Rodeck, Ulrich
AU - Argiris, Athanassios
AU - Luginbuhl, Adam J.
N1 - Funding Information:
This work was supported by the National Institutes of Health (R01DE027749, R01CA178613 to YK), the Department of Defense (W81XWH-16-1-0679 to UR) and CDMRP Breakthrough Award to YK, Bristol Myers Squibb, and the Thomas Jefferson Deans Grant (to the Jefferson Squamous Cell Working Group).
Funding Information:
YK is supported by Barry and Amy Baker Endowment, NIH R01 CA178613, R01 DE027749, Dept. of Defense CDMRP Breakthrough Award, Rowen Fund.
Publisher Copyright:
© Copyright © 2020 Merlino, Johnson, Tuluc, Gargano, Stapp, Harshyne, Leiby, Flanders, Zinner, Axelrod, Curry, Cognetti, Mannion, Kim, Rodeck, Argiris and Luginbuhl.
PY - 2020/12/2
Y1 - 2020/12/2
N2 - PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. Patients and Methods: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. Results: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8+ T cells and CD163+ macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. Conclusion: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC.
AB - PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immunotherapy-mediated treatment effects vary by site of involvement (primary tumor, lymph nodes) and determine how radiographic tumor shrinkage correlates with pathologic treatment effect. Patients and Methods: Forty-four patients enrolled in trial NCT03238365 were treated with nivolumab 240 mg intravenously on days 1 and 15 with or without oral tadalafil, as determined by random assignment, followed by surgery on day 31. Radiographic volumetric response (RVR) was defined as percent change in tumor volume from pretreatment to posttreatment CT scan. Responders were defined as those with a 10% reduction in the volume of the primary tumor or lymph nodes (LN). Pathologic treatment effect (PTE) was defined as the area showing fibrosis or lymphohistiocytic inflammation divided by total tumor area. Results: Sixteen of 32 patients (50%) with pathologic evidence of LN involvement exhibited discordant PTE between primary sites and LN. In four patients with widely discordant adjacent LN, increased PTE was associated with increased infiltration of tumor CD8+ T cells and CD163+ macrophages, whereas stromal regulatory T cells were associated with low nodal PTE. RVR correlated with PTE at both primary tumor (slope = 0.55, p < 0.001) and in LN (slope = 0.62, p < 0.05). 89% (16/18) of radiographic non-responders with T1–T3 primary sites had no (n = 7) or minimal PTE (n = 9), whereas 15/17 (88%) of radiographic responders had moderate (n = 12) or complete (n = 3) PTE. Conclusion: Nivolumab often induces discordant treatment effects between primary tumor sites and metastatic lymph nodes within subjects. This treatment discordance was also demonstrated in adjacent lymph nodes, which may correlate with local immune cell makeup. Finally, although these data were generated by a relatively small population size, our data support the use of early radiographic response to assess immunotherapy treatment effect in HNSCC.
KW - computed tomography imaging
KW - immunotherapy
KW - lymph nodes
KW - nivolumab
KW - squamous cell carcinoma of head and neck
UR - http://www.scopus.com/inward/record.url?scp=85097659839&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097659839&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.566315
DO - 10.3389/fonc.2020.566315
M3 - Article
C2 - 33344227
AN - SCOPUS:85097659839
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 566315
ER -